TY - JOUR
T1 - Clinical trial of a cancer vaccine targeting VEGF and KIF20A in advanced biliary tract cancer
AU - Murahashi, Mutsunori
AU - Tsuruta, Toshihisa
AU - Yamada, Kazunari
AU - Hijikata, Yasuki
AU - Ogata, Hisanobu
AU - Kishimoto, Junji
AU - Yoshimura, Sachiko
AU - Hikichi, Tetsuro
AU - Nakanishi, Yoichi
AU - Tani, Kenzaburo
N1 - Funding Information:
K.T. reports receiving research grants from Neopharma Japan, Co., Ltd., Neoprecision therapeutics Co., Ltd. and Shinnihonseiyaku Co., Ltd. K.T. has stocks in Neoprecision therapeutics Co., Ltd. and in Shinnihonseiyaku Co., Ltd. No potential conflicts of interest were disclosed by the other authors. S.Y. and T.H. were employees of OncoTherapy Science, Inc. and are employees of Cancer Precision Medicine, Inc..
Funding Information:
The Authors thank Michiko Ushijima for skilful technical assistance and the Center for Clinical and Translational Research, Kyushu University for their excellent assistance with the clinical trial. This work was supported by Japan Agency for Medical Research and Development (AMED), Grant Number 16lk0103008h0005 and Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17K09464.
Publisher Copyright:
© 2021 International Institute of Anticancer Research. All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Background: As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits of OCV-C01, an HLA-A*24:02-restricted three-peptide cancer vaccine targeting VEGFR1, VEGFR2, and KIF20A. Patients and Methods: Participants were patients with advanced BTC who had unresectable tumours and were refractory to standard chemotherapy. OCV-C01 was injected weekly until the discontinuance criteria were met. Results: Six participants, including four patients positive for HLA-A*24:02, were enrolled in this study for assessment of efficacy. Four out of six patients exhibited vaccine-specific T-cell responses to one or more of three antigens. Log-rank tests revealed that vaccine-specific T cell responses contributed significantly to overall survival. Conclusion: The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies.
AB - Background: As the prognosis of biliary tract cancer (BTC) is extremely poor and treatment options are limited, new treatment modalities are urgently needed. We designed a phase II clinical trial to investigate the immune responses and clinical benefits of OCV-C01, an HLA-A*24:02-restricted three-peptide cancer vaccine targeting VEGFR1, VEGFR2, and KIF20A. Patients and Methods: Participants were patients with advanced BTC who had unresectable tumours and were refractory to standard chemotherapy. OCV-C01 was injected weekly until the discontinuance criteria were met. Results: Six participants, including four patients positive for HLA-A*24:02, were enrolled in this study for assessment of efficacy. Four out of six patients exhibited vaccine-specific T-cell responses to one or more of three antigens. Log-rank tests revealed that vaccine-specific T cell responses contributed significantly to overall survival. Conclusion: The cancer vaccine had positive effects on survival, indicating that this approach warrants further clinical studies.
UR - http://www.scopus.com/inward/record.url?scp=85103177921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103177921&partnerID=8YFLogxK
U2 - 10.21873/anticanres.14907
DO - 10.21873/anticanres.14907
M3 - Article
C2 - 33788741
AN - SCOPUS:85103177921
SN - 0250-7005
VL - 41
SP - 1485
EP - 1496
JO - Anticancer research
JF - Anticancer research
IS - 3
ER -
